Dr. Bin Wang is the director of National Engineering Lab of Therapeutic Vaccines and a distinguished professor at Department of Medical Microbiology and Parasitology, Fudan University School of Basic Medical Sciences. His research area is to focus on the effects of therapeutic vaccination to activate T cell or suppress T cells and the mechanism of immune regulations. His lab recently designed a novel RSV vaccine approach against RSV infection and containing enhanced respiratory disease (ERD) by induction of Treg cells. This design has been led to develop the first Treg based vaccine and has demonstrated that a key role of Treg cell in contenting enhanced respiratory disease after challenged with RSV in animals.
Recently, this Treg based vaccine has been completed its Phase I clinical trial. His lab has also developed a novel adjuvanted HBV therapeutic vaccine against chronic HBV and tested in clinical trials. He received his his Ph.D. from the University of Cincinnati Children Hospital in 1990. He completed his postdoc training in virology and immunology at the Wistar Institute 1992. He became an instructor and then assistant professor at University of Pennsylvania Medical School in the period of 1993 to 1998. He was a professor and served as the Chairman at Department of Microbiology and Immunology for 6 years at College of Biological Sciences, China Agricultural University before he joined to Fudan University.
He has published over 150 peer-review articles and awarded 35 US and 22 Chinese patents. He serves as editorial board members for several international journals and executive members in number of scientific societies.